Jeil Pharma Holdings Inc (KRX:002620)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,760.00
-220.00 (-2.45%)
Mar 3, 2026, 3:30 PM KST
20.83%
Market Cap 137.85B
Revenue (ttm) 707.15B
Net Income (ttm) -29.41B
Shares Out 15.35M
EPS (ttm) -1,916.63
PE Ratio n/a
Forward PE n/a
Dividend 50.00 (0.56%)
Ex-Dividend Date Dec 29, 2025
Volume 38,922
Average Volume 58,404
Open 8,890.00
Previous Close 8,980.00
Day's Range 8,570.00 - 9,200.00
52-Week Range 6,960.00 - 9,920.00
Beta 0.67
RSI 63.01
Earnings Date Mar 13, 2026

About Jeil Pharma Holdings

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine... [Read more]

Sector Healthcare
Founded 1959
Employees 37
Stock Exchange Korea Stock Exchange
Ticker Symbol 002620
Full Company Profile

Financial Performance

In 2024, Jeil Pharma Holdings's revenue was 779.82 billion, a decrease of -3.01% compared to the previous year's 804.04 billion. Losses were -51.16 billion, 214.8% more than in 2023.

Financial Statements

News

There is no news available yet.